GENETHERAPY
CD20-speci cadoptiveimmunotherapyforlymphomausingachimericantigenreceptorwithbothCD28and4-1BBdomains:pilotclinicaltrialresults
BrianG.Till,1,2MichaelC.Jensen,1,3JinjuanWang,1XiaojunQian,1AjayK.Gopal,1,2DavidG.Maloney,1,2
CatherineG.Lindgren,1YukangLin,1JohnM.Pagel,1,2LihuaE.Budde,1,2AndrewRaubitschek,4StephenJ.Forman,4PhilipD.Greenberg,1,2StanleyR.Riddell,1,2andOliverW.Press1,2
1Clinical3Seattle
ResearchDivision,FredHutchinsonCancerResearchCenter,Seattle,WA;2DepartmentofMedicine,UniversityofWashington,Seattle,WA;Children’sResearchInstitute,Seattle,WA;and4CityofHopeCancerResearchCenter,Duarte,CA
Cellularimmuneresponseshavethepo-tentialtoelicitdramaticandsustainedclinicalremissionsinlymphomapatients.Recentclinicaltrialdatademonstratethatmodi cationofTcellswithchimericantigenreceptors(CARs)isapromisingstrategy.TcellscontainingCARswithcostimulatorydomainsexhibitimprovedactivityagainsttumors.Weconductedapilotclinicaltrialtestinga“third-generation”CD20-speci cCARwithCD28and4-1BBcostimulatorydomainsinpatientswithrelapsedindolentB-cellandmantlecelllymphomas.Fourpa-tientswereenrolled,and3receivedT-cellinfusionsaftercyclophosphamidelym-phodepletion.Treatmentwaswelltoler-ated,althoughonepatientdevelopedtransientinfusionalsymptoms.Twopa-tientswithoutevaluablediseaseremainedprogression-freefor12and24months.Thethirdpatienthadanobjectivepartialremissionandrelapsedat12monthsafterinfusions.Modi edTcellsweredetectedbyquantitativePCRattumorsitesandupto1yearinperipheralblood,albeitatlow
levels.Noevidenceofhostimmunere-sponsesagainstinfusedcellswasdetected.Inconclusion,adoptiveimmunotherapywithCD20-speci cTcellswaswelltoleratedandwasassociatedwithantitumoractivity.WewillpursuealternativegenetransfertechnologiesandcultureconditionsinfuturestudiestoimproveCARexpressionandcellproductionef ciency.Thisstudyisregisteredatdoc.guandang.net.(Blood.2012;119(17):3940-3950)
Introduction
AdoptiveT-celltherapyhasemergedasapromisingstrategyforthetreatmentofcancer.1-7ThechallengesofisolatingTcellsreactivetowardtumor-associatedantigensandusingsuchcellsinpatientswithadiversityofhumanleukocyteantigen(HLA)phenotypeshave,tosomeextent,beenovercomethroughtheuseofchimericantigenreceptors(CARs).Thesegeneticallyengineeredmoleculestypicallyconsistofanextracellularantigen-bindingdomainde-rivedfromamonoclonalantibody(mAb),usuallyintheformofasingle-chainvariablefragment(scFv),linkedviaspacerandtransmembranedomainstoaT-cellsignalingendodomain,mostcommonlytheCD3 chain.8CAR-redirectedTcellshavethecapacitytorecognizecell-surfacetumortargetsinanHLA-independentfashion,leadingtoantigen-speci cTcellactivation,proliferation,andcytokineproduction,andthecapacitytoeradi-catetumorsinmousexenograftmodels.9-12
Non-Hodgkinlymphomas(NHLs),particularlytheindolentB-celllymphomasandmantlecelllymphoma(MCL),areappeal-ingtargetsforCAR-basedimmunotherapybecauseoftheirsus-ceptibilitytoTcell–mediatedimmuneeffects,asevidencedbylong-termremissionsafterallogeneicstemcelltransplantation(SCT).13,14TheCD20antigenonthesurfaceofB-NHLcellsisawell-establishedimmunotherapytargetforlymphoma,withnu-merousrandomizedtrialsdemonstratingimprovedclinicalout-comesinpatientstreatedwithanti-CD20Ab.
SubmittedOctober26,2011;acceptedJanuary13,2012.PrepublishedonlineasBloodFirstEditionpaper,February3,2012;DOI10.1182/blood-2011-10-387969.
ThereisanInsideBloodcommentaryonthisarticleinthisissue.Theonlineversionofthisarticlecontainsadatasupplement.
©2012byTheAmericanSocietyofHematology
Wepreviouslyreportedtheresultsofaphase1clinicaltrialinvestigatingtheuseofanti-CD20CAR autologousTcellstotreatpatientswithrelapsedindolentNHLandMCL.15Inthatstudy,wedemonstratedthesafetyandtolerabilityofthisapproachbutfoundthattheexvivoexpansionmethodsusedwereinef cientandthattheantitumoractivityandpersistenceofthemodi edTcellsweremodest.NumerouspreclinicalstudieshavedemonstratedthatCARsendowedwithco-stimulatoryendodomains,suchasCD28,OX40,or4-1BB(commonlyreferredtoas“secondgeneration”CARs),augmentT-cellactivitybothinvitroandinvivocomparedwith rst-generationCARslackingcostimulation.16-20TheseenhancedCARsweredesignedtomimicnormalphysiology,wherebothaprimaryTCRsignalandasecondcostimulatorysignalarerequiredforfullactivationofTcells.Thebene tofCARcostimulationwasrecentlycon rmedinaclinicaltrialinwhichaCD28-containingCARconferredsuperiorinvivoexpansionandpersistencecomparedwitha rst-generationCAR.21Potentantileukemicresponseswereseeninanotherrecenttrialinwhicha4-1BBdomainwasincorporatedintotheCAR.6Severalgroupshavecombined2costimulatorydomainsintotheCARconstructandshownsuperioractivityinpreclinicalstudies.22-24WepreviouslytestedmultipleCARcon gurationsinvitroandfoundthataCARcontainingCD28andCD137(4-1BB)domains
Thepublicationcostsofthisarticleweredefrayedinpartbypagechargepayment.Therefore,andsolelytoindicatethisfact,thisarticleisherebymarked‘‘advertisement’’inaccordancewith18USCsection1734.
3940
BLOOD,26APRIL2012 VOLUME119,NUMBER17
A universal strategy for adoptive immunotherapy of...lymphoma, where all tumor cells express, CD19, ...To interrogate antigen-specific cytolytic potential,...
γδ T cells a better choice for the adoptive immunotherapy of lymphoid malignancies_医学_高等教育_教育专区。Anti-γδ TCR antibody-expanded γδ T ...
Ex vivo gene transfer for improved adoptive immunotherapy of cancer 隐藏>>...Her-2/neu breast cancer cell line and CD20-positive lymphoma (49,50). ...
Differences in the recognition of tumor-specific CD8+ T cells derived from...Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated ...
Key words: CIK cells; adoptive immunotherapy; ...[37] or their engineering to produce specific ...CD8+ NK-T cells in the treatment of lymphoma....
Adoptive immunotherapy of cancer using ex vivo expanded human gammadelta new...lymphoma cell line (Daudi), T cell lymphoma cell line(Jurkat) non-small ...
(1993) [Study of adoptive immunotherapy for metastatic renal cell carcinoma ...(CTLs) Are Equally Effective as E7-Specific CD8+ CTLs in Killing ...
graft-versusleukemia/lymphoma; GVT, graft-versus-tumor, hematopoietic stem ...Adoptive T cell cancer immunotherapy is based on the premise that T cells ...
Antitumor Immunity by T-Cell Adoptive Immunotherapy...antigen-specific T cells that facilitate their ...lymphoma, are providing opportunities to broaden ...
? ? ? Burkitt’s lymphoma B-cell lymphoma in ...Differentiation- specific antigens ? ? CALLA (CD... (Tumors secrete factors TGFb) IMMUNOTHERAPY ? ...
热门文档